Drug intelligence / Profile preview

hepatitis B virus therapeutic vaccine

Development stage
Preclinical
Lead developer
Auro Vaccines
Modality
Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intramuscular
01

Overview

The hepatitis B virus therapeutic vaccine is an **Auro Vaccines** preclinical heterologous prime-boost immunotherapy for chronic hepatitis B. It uses the PBS Vax platform: a GeneVax DNA-plasmid prime encoding hepatitis B virus antigens, co-administered with the GeneVax IL-12 plasmid molecular adjuvant and delivered by electroporation, followed by a VesiculoVax vesiculovirus-vectored boost. The program is designed to generate durable antiviral T-cell responses against cells infected with hepatitis B virus across all eight HBV genotypes, with the intended use as an adjunct to antiviral drug therapy to achieve functional control or cure of chronic infection. Preclinical small-animal development was completed; further development is on hold and the program is available for out-licensing or co-development.

Other names
8-genotype HBV vaccineHBV Therapeutic Vaccine

Beyond the preview

Go deeper on hepatitis B virus therapeutic vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on hepatitis B virus therapeutic vaccine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call